

Index

A

- AAT polymorphisms. *See* *CNRI*
- ABN-CBD. *See* *abnormal cannabidiol*
- Abnormal cannabidiol (ABN-CBD), 50, 133–134, 140–142, 145, 152, 334
- Abuse (drug/polysubstance/alcohol abuse), 38, 62, 250, 435, 487, 492, 494, 533, 541, 543–544, 546, 548, 567
- of marijuana (cannabis): 492–495, 498, 501, 505, 510, 516, 533, 543
- ACEA, 92–94, 287, 289, 338, 399–400, 419, 443, 455, 542–543
- Acetylcholine (ACh), 144, 171, 397, 426, 432–433, 437, 464, 491, 505, 508–510, 512–513, 536, 545–548, 563–565
- Acetylcholine (ACh) receptor, 16, 162
- muscarinic, 412
- M₁, 133, 135, 142, 186, 211, 432–433, 436–437, 506, 509–511
- M₃, 211
- M₄, 133, 135, 142
- nicotinic $\alpha 7$, 133, 135, 144, 490, 501–502
- ACh. *See* *acetylcholine*
- Acomplia™ (*See also: SR141716A*), 7, 35, 95–96, 262, 268, 277, 299, 307, 308, 382, 400, 401, 411, 440, 445–446, 452, 492, 529, 533, 536–539, 541, 543–547, 550, 562
- Acquired immunodeficiency syndrome (AIDS) (*See also: encephalopathy*), 96, 387
- ACTH. *See* *adrenocorticotropic hormone*
- 2-Acyl glycerols, 47, 53
- Addiction (*See also: abuse*), 140, 464, 507, 566
- Adenosine receptor A₁, 133, 142
- A_{2A}, 139, 337, 493, 515
- Adenylyl cyclase, 64–65, 78–79, 83, 85, 137, 205, 243, 298, 362, 409, 489, 534–535, 537
- subtypes, 137–138
- Adipogenesis, 121, 289, 301–302
- Adiponectin, 282, 284, 285, 289, 298–300, 307
- Adipose tissue, 121, 278–279, 283, 285, 289, 298–302, 305
- white, 284, 290, 296, 299–302
- brown, 288, 300–301
- Adrenocorticotropic hormone, 279–280, 284, 288, 538
- ADTR. *See* *agonist-directed trafficking of response*
- AEA. *See* *anandamide*
- Affective disorder. *See* *mood disorder*
- 2-AG. *See* *2-arachidonoylglycerol*
- Agonist-directed trafficking of response (ADTR), 75, 77, 83, 85
- AIDS. *See* *acquired immunodeficiency syndrome*
- Akt (PKB), 65, 79–81, 85, 242, 282, 296, 322–323, 341, 343, 349, 362, 367, 489
- Alpha-synuclein, 317, 448, 450
- Alzheimer's disease, 64, 96, 317, 319, 325, 331, 343, 347, 350–351, 395–402
- AM251, 92, 95, 134, 136–137, 141–142, 146–147, 152, 222, 262, 267–268, 287, 295, 303, 334, 336, 440, 502, 538, 541–545, 565
- AM404, 32, 39, 134–136, 147, 210, 429, 440, 444, 446–447, 454–455, 460, 538, 541–542, 544, 562
- AM630, 92, 95, 137, 141, 263, 336–337
- Amiloride-sensitive epithelial Na⁺ channel (ENaC), 134–135, 151
- Aminoalkylindole, 64, 92–94
- AMP-activated protein kinase $\alpha 1$ and $\alpha 2$, 280, 283–285, 287, 289, 296–299, 303–304
- Amphetamine (and methamphetamine), 38, 443, 487, 507, 516

- AMPK α 1 and α 2. *See AMP-activated protein kinase α 1 and α 2*
- AMT. *See anandamide membrane transporter*
- Amygdala, 39, 169–170, 173, 180–181, 188–190, 208, 241, 293, 341, 396, 425, 492, 514, 534, 538–539, 548, 563–565
- Amyotrophic lateral sclerosis, 96, 319, 385
- Anandamide (AEA), 7, 10, 15, 39–40, 47–52, 55, 66, 81, 84, 92–94, 102, 108–109, 116–117, 121, 131–132, 133–134, 137–138, 141–142, 144–145, 147–153, 161, 181, 204–205, 208, 212–213, 226–227, 245–249, 262–263, 265, 268, 277, 284, 287–292, 299–305, 318–321, 324, 333–339, 342, 345, 347, 362–363, 378, 383–384, 387, 399, 401, 413–414, 419, 427–430, 432–435, 437, 440, 442–446, 492–493, 496–497, 500, 502, 538, 541–544, 562, 564, 567
- degradation/ metabolism, 31–32, 35–38, 187–188, 190, 241, 429–430, 567
- AEA membrane transporter (AMT)/ AEA uptake, 32–35, 52, 429, 543, 567
- synthesis/ release, 15–21, 24–25, 64, 109, 184–185, 239–241, 428, 433
- tissue-specific distribution, 182–184, 239, 428
- Antidepressant, 246, 266, 530–531, 533–550, 567
- Antioxidant, 262, 321, 397, 400–401, 451, 453–456, 462–463
- Antipsychotics, 485–487, 496–497, 501, 503–504, 513, 515–516
- Anxiety, 5, 31, 36, 38, 122, 180, 307, 442, 532–534, 539–540, 546–548, 550, 559–568
- anxiety disorder, 96, 530, 533, 559–568
- Anxiolysis, anxiolytics, 246, 540, 559–568
- Apoptosis, 37, 79, 81, 106, 295, 319, 321–322, 324, 341, 343, 348, 364–369, 385
- Appetite. *See feeding*
- Arachidonic acid, 3, 7, 15–17, 20–25, 31–32, 37, 47, 49, 54, 111–112, 131–132, 148, 152, 184, 263, 302, 304, 347, 350, 489, 491
- Arachidonylethanolamine. *See anandamide*
- 2-Arachidonoylglycerol (2-AG), 7, 15–16, 21, 47, 54–55, 64, 80, 82–84, 92–93, 96, 132–134, 137–138, 141, 143–145, 148–150, 153, 204–205, 208, 214, 216–219, 245–246, 248, 263–264, 278, 284, 289–291, 297, 299–301, 303–306, 318–320, 322–323, 334–337, 341–342, 362–363, 378, 383–384, 401, 412–414, 419, 428, 430, 433–437, 491–493, 496–497, 502, 506, 510
- degradation/ metabolism, 31, 38–40, 189–190, 241, 430
- synthesis/ release, 15, 21–25, 185–186, 210, 212–213, 222, 226, 239, 243, 428, 433
- tissue-specific distribution, 182–184, 239, 428
- 2-Arachidonoyl lysophosphatidic acid (LPA), 23–24
- 2-Arachidonoylglycerol ether. *See noladin ether*
- Arcuate nucleus, 181, 280, 289
- Astrocyte, 17, 22, 60, 149, 174, 176, 294, 319, 340–342, 344–346, 348, 350–351, 361–362, 366, 395–398, 400, 402, 427, 456, 458, 462
- Attention, 485, 494, 496, 504–505, 508, 511, 513, 535
- Attention deficit hyperactivity disorder, 96, 249, 498, 539, 548–549
- Autoimmune encephalomyelitis (EAE), 317, 323, 344, 375–376, 380, 383–387
- A β . *See beta-amyloid*
- B**
- Basal ganglia, 49, 59, 62, 116, 139, 146, 152, 169, 171–172, 180–183, 186, 188–189, 204, 208–210, 212, 240–241, 282, 318, 341, 343, 346, 398, 415–417, 423–466, 487, 491–493, 502, 505–511, 514–515, 534
- BDNF. *See brain-derived neurotrophic factor*
- BDNF receptor. *See receptor-tyrosine kinase B*
- Benzodiazepine, 413, 568
- Beta cells. *See Langerhans islet*
- Beta-amyloid (A β), 318, 335–336, 339, 347, 395–397, 399–402
- Beta-arrestin, 66, 69
- Bipolar disorder, 531, 533
- Bladder, 50, 120, 380
- dysfunction, 375, 380
- hyper-reflexia, 10, 120
- Blood flow (cerebral), 282, 294, 340, 532
- Bradykinesia, 447–448, 450–452, 466
- Bradykinin, 21, 110–112, 119, 150, 187
- Brain-derived neurotrophic factor (BDNF), 140, 243, 248, 296, 321–322, 417, 457, 464, 499–501, 537–538

C

- Ca²⁺ channel, 64–65, 79, 111, 117, 145–147, 204–205, 243, 489
- Ca_v1 (L-type), 133, 135, 145–146, 432–433
- Ca_v2 (N, P/Q, R-types), 65, 133, 135, 145–146, 319, 362
- Ca_v3 (T-type), 133, 135, 145
- CAG repeats (*See also: huntingtin*), 456, 458
- cAMP (cyclic adenosine monophosphate), 6, 64–65, 79, 137, 139, 148–149, 151, 279, 285, 288, 292, 298–299, 409, 493, 515, 534–535, 537
- Cancer (and tumor; *See also: glioma*), 4, 64, 76, 81, 96–97, 116, 140, 259–261, 343, 361–371, 488–489
- Cannabidiol (CBD), 5–6, 96, 133–134, 139, 141, 261–265, 267, 269–271, 318, 321, 323, 334, 337, 363, 379, 387–388, 399–400, 408, 443, 447, 453–454, 456, 461–462, 485, 502, 515–516, 562, 566–568
- Cannabimimetic, 15, 47–48, 95, 386–387
- Cannabinol (CBN), 6, 133–134, 150, 334, 443, 461
- Cannabis, 3–6, 38, 9, 60, 75, 91–92, 223–224, 226, 237, 238, 249–250, 260–261, 267, 269–271, 287, 324–325, 362, 363, 375, 377–382, 387–388, 400, 408, 419, 451, 456, 464, 485, 489, 494–495, 497, 500, 502–505, 508, 512–513, 515, 529, 532–534, 536, 543–544, 546, 559, 562
- Cannabis spp. (sativa/indica)*, 3–4, 6, 59, 75, 203, 237, 362, 408, 442
- Capsaicin, 49–50, 102, 119–121, 134–135, 142, 144, 146–147, 174, 180, 291, 301–302, 445–446, 455, 460
- Capsaicin receptor (*See also: TRPV₁ receptor*), 9, 10, 150
- Capsazepine, 9, 49, 108, 119–120, 134–136, 144, 146–147, 149, 151, 386, 446
- Carcinoma. *See cancer*
- Caspase-3, 319, 323, 324, 462
- CB₁ receptor agonist, 24–25, 64–66, 79, 91–94, 96–97, 133–134, 137–138, 143, 243, 246
- antagonist/ inverse agonist, 7–8, 35, 37, 39, 68, 95–97, 133–134, 137, 545
- cloning, 7, 60–62, 91, 346, 362
- desensitization, 66–69, 137, 242, 289, 293–294, 319
- dimerization, 63, 137, 139, 289, 493
- internalization, 66–69
- mRNA expression, 62, 164–173, 175–178, 241, 250, 295, 346, 412, 416, 424–426, 431, 448, 459, 492, 497
- signal transduction, 64–66, 242–243
- splice variants, 61–62, 133–135, 138, 177
- structure, 60–62
- trafficking, 67–69
- CB₂ receptor agonist, 24–25, 76–77, 81–82, 84, 91–94, 96–97, 133–134
- antagonist/ inverse agonist, 77, 80, 82, 84, 95–97
- cloning, 76, 91, 362
- desensitization, 82
- internalization, 82–83
- mRNA expression, 77–78, 338, 341, 497
- signal transduction, 78–82
- structure, 76–77
- trafficking, 82–84
- CB₃ receptor, 132, 146, 566
- CBD. *See cannabidiol*
- CCK. *See cholecystokinin*
- Ceramide, 79, 81, 85, 243, 294, 319, 341, 364–368
- Cerebellum, 49, 62, 104, 151, 173–174, 180–183, 186, 188–189, 206, 207, 210, 212, 215–219, 241, 292, 398, 434, 437, 493, 510
- Cesamet[™] (*See also: Nabilone[™]*), 96, 143, 363, 382
- Channel blockade, 133–135, 143–150
- Chemotherapy, 259–261, 266, 268–269, 370, 387
- Chili (or chilli) pepper, 4–5, 8, 107, 180
- Cholecystokinin (CCK), 166, 167, 169, 189, 211, 223, 248, 266, 280–282, 284, 306, 503
- Cholesterol, 33, 287, 299, 307–308
- Cingulate cortex, 341, 496
- Cisplatin, 260, 260–266, 366
- c-Jun N-terminal kinase (JNK), 65, 81, 243, 324, 362
- Clathrin-dependent endocytosis, 66, 69
- Clozapine, 488, 499, 502, 503, 516
- CNRI*, (CB₁ receptor gene), 62, 497, alleles, 61–62
- polymorphism, 250, 305, 407–499, 533–534
- Cocaine abuse, 324, 307, 533
- Cognitive impairment (and cognitive/ memory deficit/ disturbance/ dysfunction/ impairment), 224, 238, 246, 249, 295, 323, 339, 347, 395, 401, 456, 488, 490, 492, 500–501, 503, 532, 548–549
- Coincidence detector, 205, 212, 220–221, 432, 505–506
- Corticosterone. *See glucocorticoid*
- Corticotrophin releasing hormone (CRH), 172, 280, 288, 538–539

COX-2. *See cyclooxygenase-2*
 CP55940, 62, 64, 77, 82–84, 92–94, 133–134,
 137, 138, 140, 141, 144–146, 148, 149,
 151, 224, 264, 333–334, 397, 440, 460,
 496, 503, 541–544, 546
 Cre/loxP technique, 415
 CRF. *See corticotrophin releasing hormone*
 CRH. *See corticotrophin releasing hormone*
 Cyclooxygenase-2 (COX-2), 31–32, 37,
 39–40, 49, 111, 147, 190, 205, 263, 350
 Cytochrome-*c* release, 81, 317, 324

D

DAGL. *See diacylglycerol lipase*
 DARP-32. *See dopamine- and cAMP-
 regulated phosphoprotein of 32 kDa*
 DAT. *See dopamine transporter*
db/db mouse, 288, 297, 301, 305
 Delta⁸-tetrahydrocannabinol (Δ^8 -THC), 6,
 91–93, 96, 261, 461
 Delta⁹-tetrahydrocannabinol (Δ^9 -THC),
 5–6, 64, 75, 91–94, 96–97, 133–134,
 137–138, 141, 143–146, 148, 150, 224,
 226, 237–238, 248–225, 260, 263–265,
 269–271, 287–289, 292–294, 303, 318–
 325, 333, 335, 337–338, 341, 362–363,
 365–366, 369–370, 378–380, 382, 385,
 387–388, 399, 402, 408, 439–444, 447,
 451, 453–454, 456, 461–462, 492–494,
 500, 502–504, 513–514, 532, 537, 541
 Delusion of alien control, 512, 516
 Dependence. *See abuse and see addiction*
 Depolarization-induced suppression of
 excitation (DSE), 208, 210,
 215–216, 218–219, 409, 411,
 414, 430, 433–436, 510
 Depolarization-induced suppression of
 inhibition (DSI), 207–209, 211–214,
 216, 224, 226, 411, 414, 425, 430, 433,
 435, 436–438, 503, 509–510, 514
 Depression (*See also: mood disorder*), 36,
 38, 144, 307, 486, 530–535, 539–540,
 546–549, 566, 568
 Development, neuronal, 59, 238, 499,
 238–239, 242–244, 246, 248–249, 490,
 499–501, 506
 of the brain/ CNS, 19, 140, 186–187, 206,
 237–245, 247, 249–250, 343, 349, 488,
 491, 493, 499–501, 506, 514
 DG lipase. *See diacylglycerol lipase*
 Diabetes, 121, 286, 295
 type-I, 295–296
 type-II, 121, 305, 307–308

Diacylglycerol, 15, 22, 25, 185, 205,
 212, 243, 506
 Diacylglycerol lipase (DAGL α and β),
 22–23, 25, 185–187, 210, 212–213,
 217, 222, 226, 239–241, 248, 305,
 383, 428, 433–436, 445, 501
 Diet-induced obesity, 287, 290,
 300–308
 Dihomo- γ -linolenylethanolamide,
 50–51
 Dizocilpine. *See MK-801*
 Docosatetraenylethanolamide, 50–51
 Dopamine- and cAMP-regulated
 phosphoprotein of 32 kDa (DARP-32),
 515, 535
 Dopamine receptor D₁, 171, 426, 432, 435,
 506–507, 509–511
 D₂, 171, 432, 506–507, 509–511
 D₂-like, 486, 490, 496
 Dopamine transporter (DAT), 134–135,
 152, 427, 440–441, 446, 490
 Dream, 512–515
 Drug abuse. *See abuse*
 DSE. *See depolarization-induced suppression
 of excitation*
 DSI. *See depolarization-induced suppression
 of inhibition*
 DSM-IV, 530–531, 539
 Dynammin, 67–68
 Dyskinesia (*See also: levodopa*), 446–448,
 450–452, 464
 tardive dyskinesia, 96, 464
 Dysphoria, 5, 530, 533
 Dystonia, 446–447, 464–466

E

EAE. *See autoimmune encephalomyelitis*
 ECT. 1) *See endocannabinoid transporter*
 2) *See electroconvulsive treatment*
 edg-like lysophospholipid receptor, 142
 EEG. *See electroencephalogram*
 EGF. *See epidermal growth factor*
 Eicosanoid, 64, 77, 92, 343, 348, 446
 Electroconvulsive treatment, 535, 548
 Electroencephalogram (EEG), 513–514,
 532, 545–546
 Emesis. *See nausea/ vomiting*
 Encephalitis (*See also: neuroinflammation
 and autoimmune encephalomyelitis*),
 348, 350
 Encephalopathy, diabetic, 295
 HIV-associated encephalopathy
 (HIVE), 343

Endocannabinoid. *See anandamide and 2-arachidonoylglycerol*
 endocannabinoid release, *see anandamide synthesis/ release and see 2-arachidonoylglycerol synthesis/ release*
 endocannabinoid system, 5–8
 Endocannabinoid transporter (ECT), 187
 (*See also: anandamide uptake*)
 Endovanilloid system, 8–10, 49, 131–132, 452
 Epidermal growth factor (EGF), 140, 243, 368
 Epilepsy, (epileptiform) seizure, 22, 145, 164, 250, 317, 407–419, 514
 Epileptiform seizure. *See epilepsy, (epileptiform) seizure*
 Epinephrine (adrenaline), 279, 283
 Epithelioma, thyroid (*See also: cancer*), 363
 ERK. *See extracellular signal-regulated kinase*
 Excitability, 147, 408
 dendritic excitability, 213
 hyperexcitability, 407, 411, 417
 membrane excitability, 149
 neuronal excitability, 102, 409, 411, 433, 515
 Excitotoxicity, 320–323, 344–345, 377–378, 384, 431, 435, 447–448, 450–451, 453, 457, 459, 461, 463, 538
 Extracellular signal-regulated kinase (ERK), 65, 80–81, 83–85, 113, 243, 247, 320, 322–323, 336, 341, 362, 367

F
fafa (Zucker) rat, 121, 211, 288, 297–298, 305
 FAAH. *See fatty acid amide hydrolase*
 FAK. *See focal adhesion kinase*
 Fatty acid, 17, 19–20, 31, 47, 51–55, 278, 280, 283, 296–300, 302, 509
 β -oxidation, 278, 283, 285, 289, 297, 300, 302, 303
 polyunsaturated (and ω 3 and ω 6 PUFA), 182, 304
 synthesis, 283, 285, 286–287, 297, 299, 302, 303
 fatty acid amide hydrolase (FAAH)
 (*See also phenylmethylsulfonyl fluoride*), 15, 17, 31–40, 54, 150, 170, 187–190, 221, 239, 241, 245–246, 250, 262, 268, 284, 302, 304–306, 320, 331, 340–341, 343, 346–351, 388, 398, 414, 419, 428–430, 434, 442, 444, 451, 466, 497, 539, 541–543, 562, 564, 567
 Febrile seizure (*See also: epilepsy, (epileptiform) seizure*), 226, 410–412

Feeding (and appetite), 37, 52–54, 96, 143, 183, 268, 277, 281, 284–285, 287–289, 297–298, 304, 308, 363, 511, 540, 560
 FGF. *See fibroblast growth factor*
 Fibroblast growth factor (FGF), 140, 243, 322, 368, 464
 Focal adhesion kinase (FAK), 65, 323, 362

G
 G protein-coupled receptor kinase 3, 66
 GABA (and GABA-ergic; *see also DSI, LTP*), 60, 66, 115, 139, 146–148, 175, 207–208, 214, 216, 225, 250, 292, 411, 417, 419, 423–424, 426, 436–437, 439, 441, 457, 465, 491, 499, 502–503, 510, 513, 564
 GABA receptor GABA_A, 412
 GABA_B, 64, 170, 440
 Gap junction, 149
 GPCR-associated sorting protein (GASP1), 67
 GDNF. *See glial cell-derived neurotrophic factor*
 GH. *See growth hormone*
 Ghrelin, 280–282, 284–285, 288–289, 303, 306
 Glial cell-derived neurotrophic factor (GDNF), 114, 119
 Glioblastoma multiforme (GBM). *See glioma*
 Glioma, 79, 81, 341, 344, 361–371
 Globus pallidus, 62, 116, 425–426, 435, 438, 449, 457
 Gucagon, 279–280, 283, 290–291
 Glucocorticoid, 22, 190, 270, 280, 284, 288, 306, 537–539, 542–543
 Gluconeogenesis, 279, 285, 289
 Glucose, 278–280, 282, 282–283, 285–296, 299–300, 303, 306–308, 318, 320, 340–341, 496
 oxidation, 289, 294, 299, 303, 341
 tolerance, 287, 289–291
 uptake/ transporter, 279, 282–283, 285, 289–290, 292–295, 303
 Glucosensing, 280
 GLUT. *See glucose transporter*
 Glutamate (and glutamatergic; *see also DSE, LTD, LTP, excitotoxicity*), 60, 66, 139–140, 146–148, 152–153, 164, 166–169, 171–174, 187–189, 206, 208–209, 213–218, 220, 224, 227, 249, 288, 292, 317–322, 344, 377–378, 384, 397, 399, 409–419, 423–427, 430–436, 438, 440–441, 449, 451, 457, 461, 463, 465, 490–492, 499, 502, 505–506, 509–510, 513, 515, 534, 547, 564

Glutamate receptor, 162, 317, 342, 409, 413, 488, 568
 AMPA/kainate, 215, 217–220, 225, 249, 319
 GluR_{1,2,3}, 149
 mGluR_{1,5}, 185–186, 191, 211–213, 216–217, 220–221, 432–434, 436, 438–439, 488, 491–492, 500–501, 506–508, 511
 NMDA, 16, 134–135, 149, 151, 153, 206, 210, 215, 218, 220–221, 318–320, 344, 462, 487–488, 490, 493, 499, 502, 547
 Glutamate transporter, (re)uptake, 136, 152, 166, 218, 249, 399, 418, 435–436
 Glycine, 145, 149, 151, 490, 493, 499, 502
 Glycine receptor, 133, 135, 145, 149, 151,
 Glycine transporter, 49, 134, 136, 153, 490, 493
 Glycogen, 278–279, 282–283, 287, 290, 294, 341
 Glycogen phosphorylase, 279, 290
 Glycogen synthase kinase 3 (GSK3), 65, 243, 282, 296, 399, 499, 535, 537
 Glycogenolysis, 279
 Glycolysis, 280, 283, 286, 290, 299, 303
 GPR119, 37, 53
 GPR55, 60, 133–134, 141, 179, 182, 227, 238, 250, 559, 566
 Growth hormone, 279–280, 287, 300
 Growth hormone secretagogue receptor.
See ghrelin
 GSK3. *See glycogen synthase kinase 3*

H

Hallucination, 485, 487, 494, 504, 514
 Hashish, 3–5, 287
 hCB_{1A} and hCB_{1B}. *See CB₁ receptor splice variants*
 Heat receptor. *See TRPV₁ receptor*
 Hebbian learning, 219
 Hemp. *See Cannabis spp. (sativa/ indica)*
 Hepatocyte. *See liver*
 Hippocampus, 21, 39–40, 49, 53, 62, 66–68, 116, 122, 137–138, 140, 144–146, 148, 151, 164, 167–169, 171, 173, 180–183, 185–186, 188–190, 206–208, 212, 214, 223–224, 226, 240–241, 246, 248–250, 293–296, 318–320, 322–324, 341, 346, 396, 398, 401, 407, 409–413, 415–419, 430, 434, 437, 463, 491–494, 499–500, 510, 514, 534, 537–539, 542–543, 546, 548, 550, 563–565

HIV-1-associated dementia. *See encephalopathy*
 Homer₁, 506–508
 HPA axis. *See hypothalamo-pituitary-adrenal axis*
 5-HT. *See serotonin*
 HU-210, 64, 77, 81–82, 92–94, 133–134, 137–138, 140, 145, 150, 246, 248–249, 264, 267, 294, 297–299, 302, 323, 335, 339, 341, 345, 363, 399–400, 455, 500, 538, 541–543
 Huntingtin, 456, 458, 461–462
 Huntington's disease, 343, 345, 423–424, 445–447, 454, 456–464, 466, 516
 6-Hydroxydopamine (6-OHDA), 426–427, 447, 449, 452–455
 Hyperexcitability. *See excitability*
 Hyperpolarization-activated cyclic nucleotide-gated channel type 1 (HCN1), 134–135, 149
 Hypofrontality, 490, 534, 538, 549
 Hypothalamo-pituitary-adrenal (HPA) axis, 278, 281, 288, 535, 538–539, 548
 Hypothalamus, 9–10, 21–22, 115–116, 172, 180–181, 183, 188–190, 208, 213, 278, 280–282, 284–285, 288–289, 297–298, 300, 302, 304–305, 308, 538, 543

I

IGF-1. *See insulin-like growth factor-1*
 Imidazoline receptor, 133–134, 141–142
 Immune cell/ system/ tissue (*See also: leukocyte and see also: microglia*), 7, 75–76, 78–80, 82–85, 150, 163, 179, 292, 331, 346–347, 362, 497
 function/ modulator/ response, 50, 60, 79, 85, 331, 344, 347, 362, 376, 378, 382–387, 402, 489, 497, 506
In utero cannabis exposure, 237, 250
 Indomethacin, 37, 263
 Inflammation (*See also: neuroinflammation and see also: pain*), 5, 17, 22, 31, 35–36, 38, 52, 59, 76, 78, 85, 96–97, 106–107, 111, 113–114, 118–120, 122, 177, 184, 188, 190–191, 344, 348–350, 397, 402, 450, 459, 489
 iNOS, 321, 336, 345, 399–400
 Insulin, 49, 121, 277, 279–280, 282–287, 289–292, 296, 299, 306–308
 insulin-like growth factor-1 (IGF-1), 280, 282–284

interleukin IL-1ra, 344–345
 IL-1 α , 332–333, 335, 338
 IL-1 β , 190, 332–336, 338, 343, 345
 IL-2, 37, 50, 80, 143, 462
 IL-4, 85, 344
 IL-6, 332–333, 336, 343–345,
 IL-10, 344
 inverse agonist (*See also: AM251, AM630, SR141716A, SR144528*), 84, 91–92,
 94–97, 136, 268, 442, 445, 544
 iodoserineratoxin (I-RTX), 50, 117, 134,
 136, 146
 I-RTX. *See iodoserineratoxin*
 Ischemia, 16, 278, 295, 317–318, 320–321,
 325
 Itch, 120
 JNK. *See c-Jun N-terminal kinase*
 K⁺ channel, 8, 64, 66, 147–148, 205, 210, 489
 A-type (K_v and K_v), 66, 147–148
 Ca²⁺-activated BK_{Ca}, 151
 delayed rectifier K_v, 133, 135
 GIRK, 243, 362
 K_{ATP}, 280
 Shaker family K_v 1.2, 133, 135, 148
 two-pore domain acid-sensitive TASK,
 134–135, 148, 179, 181–182, 227
 Kainate (model), 16, 149, 318–319, 538
 knockout (*-/-*), CaMK-CB₁ receptor, 410,
 415, 417
 CB₁ receptor (*CNRI^{-/-}*), 8, 53, 177,
 245–246, 249, 288, 296, 298, 302,
 320–321, 442, 445, 500, 562
 CB₂ receptor, 8, 137, 442
 DAT, 446
 FAAH, 35, 37–38, 245–246, 542
 GABA-CB₁ receptor, 415–417
 Glu-CB₁ receptor, 415–417
 IGF-1, 282
 TASK-1, 148
 TRPV₁ receptor, 118–119, 301

L

Langerhans islet, 49, 115, 121, 284, 290,
 291, 305
 L-DOPA. *See levodopa*
 Learned helplessness, 538, 540
 Leptin, 183, 277, 280, 282, 284–285,
 287–289, 296–297, 299–301,
 305–206
 Leukocyte, 54, 76, 84
 Levodopa (L-DOPA), 448–450, 452
 levodopa induced dyskinesia (LID), 97,
 447–448, 450–452, 464

Limbic system, 53, 183, 246, 249, 281, 282,
 292–294, 342, 383, 491, 508–509, 511,
 514, 539
 2-Linoleoylglycerol, 24
 Lipogenesis, 278, 283, 285–286, 298–299, 302
 Lipolysis, 285, 298–300, 303, 306
 Lipopolysaccharide (LPS), 16, 22, 50, 78, 122,
 333–337, 344–345
 Lipoxygenase, 31–32, 37, 39, 108, 112
 Liver, 35, 97, 137, 278–279, 282, 284–285,
 287, 289, 299, 302–303, 305–307, 371
 Locomotor activity. *See Motor behaviour/*
control/ dysfunction/ effect
 Long-term depression (LTD), 203, 205–223,
 225–226, 431–435, 437–439, 451,
 464, 506
 Long-term potentiation (LTP), 15, 206,
 209, 213–214, 218–226, 295, 325,
 431, 537, 550
 LPA. *See 2-arachidonoyl lysophosphatidic*
acid
 LPS. *See lipopolysaccharide*
 LTD. *See long-term depression*
 LTP. *See long-term potentiation*

M

MAGL. *See monoacylglycerol lipase*
 MAPK. *See mitogen-activated protein kinase*
 Marijuana. *See cannabis*
 Marinol™ (*See also delta⁹-*
tetrahydrocannabinol), 96, 363,
 380, 387
 Medium spiny neuron (MSN), 171, 186, 212,
 240, 415, 428, 431–437, 457, 459, 463,
 505
 Melanoma (*See also: cancer*), 363, 367–368
 Membrane fluidity (bilayer stiffness), 6, 147
 Memory dysfunction. *See cognitive*
impairment
 meso(cortico)limbic area, 491, 494, 502,
 533, 550
 microglia, 22, 24, 60, 78, 82–84, 140, 163,
 189, 323, 331–341, 343–349, 351, 362,
 384–385, 395–402, 427, 447, 455–456,
 458, 462–463, 465, 490
 Migration, neuronal, 247–248, 506
 Mitogen-activated protein kinase (MAPK), 65,
 79–81, 83–85, 139, 243, 294, 317, 322,
 362, 367, 399, 493, 535, 537
 MK-801 (dizocilpine), 210, 487–488, 499, 502
 monoacylglycerol lipase (MAGL), 31, 37,
 39–40, 187, 189–190, 239, 241,
 305–306, 341, 430, 444, 451, 466

- Mood disorder, 529–531, 533–534, 536, 547–548
- Motivation, 485, 494, 496, 498, 508, 511, 530, 532, 535, 548
- Motor behaviour/ control/ dysfunction/ effect, 5–6, 15, 55, 97, 139, 171, 217, 219, 238, 250, 292, 296, 331, 338–339, 376, 384, 423–424, 426, 428–429, 431, 434, 438–439, 442–447, 450–451, 454, 456, 458, 460, 464–465, 488, 493, 511–512, 514–515
- MPTP, 449, 451–452
- Multiple sclerosis, 35, 64, 96, 174, 317, 323, 331, 342–343, 345, 349–350, 351, 375–388, 465
- Myelin (also demyelination, myelination, remyelination), 325, 338, 340, 342–343, 349, 375–378, 388
- N**
- Na⁺ channel, 8, 32, 133, 135, 147, 412
- Nabilone, 96, 143–144, 260, 264, 363, 370, 382, 451
- N-acetyl ethanolamine, 18, 47, 50–51, 54, 240, 304
- NADA. *See N-arachidonoyldopamine*
- NAPE. *See N-arachidonoylphosphatidylethanolamine*
- N-arachidonoyldopamine (NADA), 49–50, 108, 116, 133–134, 148–149, 180–182, 227, 291
- N-arachidonylethanolamine. *See anandamide*
- N-arachidonoylglycine, 16, 25, 47–48, 143
- N-arachidonoylphosphatidylethanolamine (NAPE), 18–21, 24–25, 109, 184–185, 204–205, 240–241, 304–305, 428, 433, 445
- N-arachidonoylserine, 47–48, 50,
- N-arachidonoylserotonin, 36
- Nausea/ vomiting (and emesis), 96–97, 179, 259–271
- anticipatory, 259–262, 268–271
- Necrosis, 278, 292, 399
- Nerve growth factor (NGF), 106, 111–114, 119, 121 322, 345, 368, 490, 501
- Neurodegeneration, 23, 283, 317–319, 321, 323, 325, 332, 342–344, 346, 351, 375–377, 384–385, 395–397, 399, 402, 407, 450, 453–454, 456, 458–459, 463, 466
- Neurogenesis, 59, 237–239, 241, 243, 245–247, 296, 322, 324, 463, 499–501, 535, 537–539, 543
- Neuroinflammation, 78, 80, 84, 317, 323, 325, 331–351, 378, 383–384, 386, 388, 458, 463
- Neurokinin 1 (NK₁) tachykinin receptor/ receptor for substance P, 180, 260
- Neuropeptide Y, 280, 284, 288
- Neuroprotection, 148, 243, 295, 317–325, 349–350, 383–384, 397, 399–400, 402, 446, 453–455, 461–463
- NFκB, 323, 399–400
- NGF. *See nerve growth factor*
- NGF receptor. *See receptor-tyrosine kinase A*
- Nightmare. *See dream*
- Nitric oxide, 215, 217, 247, 320, 322, 332, 455, 462
- 3-Nitropropionic acid (3-NP), 457–460, 462
- N-linolenylethanolamide, 50–51, 54
- N-linoleylethanolamide, 51, 54
- NO. *See nitric oxide*
- Nociceptive neuron. *See sensory neuron*
- noladin ether 53–55, 82–84, 92, 94, 134–136, 138, 141, 182, 383, 399
- N-oleoyldopamine (OLDA), 108
- N-oleylethanolamide (OEA), 32, 36–37, 50, 52–54, 134, 136
- Noradrenaline. *See norepinephrine*
- Norepinephrine (NE), 141, 531, 535–536, 542, 545, 565
- N-palmitoylethanolamide (PEA), 25, 36–37, 51–54, 134, 136, 141, 143, 147, 184, 227, 334–335, 338, 419, 496–497
- Nucleus tractus solitarius. *See solitary tract*
- O**
- O-arachidonylethanolamine. *See virodhamine*
- ob/ob mouse, 288, 297, 301, 305
- Obesity, 62, 64, 76, 96, 121, 277–278, 280, 284, 287–288, 290, 297–299, 301–308, 533, 546, 548–549
- OEA. *See N-oleylethanolamide*
- 6-OHDA. *See 6-hydroxydopamine*
- OLDA. *See N-oleoyldopamine*
- Oleamide, 36, 92, 94, 140
- Oligodendrocyte (*See also: progenitor*), 188, 340, 342–343, 345–346, 349, 351, 361, 366, 376, 429
- OMDM-1: 336, 339, 541
- OMDM-2, 339, 414, 429, 444, 543
- OMIM114610. *See CNR1*
- opioid receptor, δ, 83, 85
- μ, 139
- Orexin receptor, 213, 280, 289

- Oscillation, neuronal, 223–224, 226, 503
 Oxidative stress, 32, 317, 320–322, 342, 351, 384, 399, 401, 448, 457, 459
- P**
- pain (*See also: analgesia*), 4–5, 9, 35, 49, 52, 59, 76, 96–97, 102, 107, 109, 112, 118–120, 140, 164, 173–174, 176, 180–181, 187–188, 375, 377, 379, 381, 489, 564
 neuropathic, 35–36, 52, 76, 97, 119–120, 149, 188, 379
 inflammatory, 5, 36–38, 107, 118–119
- Pain receptor. *See TRPV₁ receptor*
- Paired-pulse facilitation (PPF), 207, 211, 222
- 2-Palmitoylglycerol, 24
- Pancreas. *See Langerhans islet*
- Parkinson's disease, 64, 76, 97, 317, 343, 423–424, 429, 446, 447–453, 455, 534
- Partial agonist, 24, 92–94, 97, 382
- PEA. *See N-palmitoylethanolamide*
- Perceptual alteration/distortion, 5, 203, 223–224, 494, 501, 503–504, 511, 530
- Peroxisome proliferator-activated receptor (PPAR), 143
 α , 37, 53, 133, 135, 143, 284, 286
 γ , 37, 133, 135, 143, 286, 298–301, 303
 δ , 143, 301
- Phencyclidine, 487, 496, 499, 502
- Phenylmethylsulfonyl fluoride (PMSF), 35, 302, 419, 543
- Phosphatidic acid, 24
- Phosphatidylinositol, 22–23
- Phosphatidylinositol-4,5-bisphosphate (PIP₂), 509, 112–113, 118, 506, 509–510
- Phosphoinositide-3-kinase (PI₃K), 79–81, 85, 106, 112, 242, 282, 317, 322–323, 341, 343, 349, 362, 489, 535
- Phospholipase A₁, 22–23, 185
- Phospholipase A₂, 120, 350, 535
- Phospholipase C α , 243
- Phospholipase C β (_{1–3}), 20, 22–24, 80, 185–187, 205, 210–213, 215, 217, 220–221, 335, 383
- Phospholipase C γ , 106, 112
- Phospholipase D, 15, 16, 18–20, 24, 109, 184, 240, 249, 428
- Phytocannabinoid, 5, 6, 59, 203, 246, 320, 387, 443, 451, 453, 454, 461, 462, 466, 515, 566
- PI₃K. *See phosphoinositide-3-kinase*
- Pilocarpine (model), 22, 411–412
- PIP₂. *See phosphatidylinositol-4,5-bisphosphate*
- PKA. *See protein kinase A*
- PKB. *See Akt*
- PKC. *See protein kinase C*
- PLC. *See phospholipase C*
- PMSF. *See phenylmethylsulfonyl fluoride*
- polysubstance (ab)use. *See abuse*
- POMC. *See proopiomelanocortin*
- PPAR α , γ , δ . *See peroxisome proliferator-activated receptor α , γ , and δ*
- Prefrontal cortex (PFC), 17, 38, 165, 171, 321, 435, 487, 491–492, 496, 499–501, 503, 505, 508–509, 534, 536–538, 548, 564–565
- Pre-pulse inhibition (PPI), 488, 501–502
- Progenitor, neuronal, 140, 169, 237–238, 242–247, 250, 324, 342, 463, 493, 500
 oligodendrocyte, 79, 81, 343
- Proopiomelanocortin (POMC), 280–281, 288–289
- Prostaglandin, 111, 190, 263
- Prostaglandin-amid, 32, 37
- Protein kinase A (PKA), 64, 78, 112–113, 118, 148, 205, 209, 220, 243, 279, 288, 292, 320–321, 337, 489, 506, 515, 535, 537
- Protein kinase B (PKB). *See Akt*
- Protein kinase C (PKC), 49, 53, 106, 111–114, 118, 175, 215, 217, 243, 337, 506, 515, 537
- Psychomotor, 6, 442, 494, 515, 530, 546
- Psychosis, 485–488, 494–495, 506, 508, 512, 514, 516
- PTPN22 (phospho-anandamide phosphatase), 184–185, 240
- PUFA. *See fatty acid*
- R**
- Radioligand binding, 142, 180, 346, 496
- Rap1, 249
- Ras, 113
- Reactive oxygen species, 50, 319, 321, 324, 343, 455, 462
- Receptor convergence, 64
- Receptor-tyrosine kinase A (TrkA), 106, 112, 119
- Receptor-tyrosine kinase B (TrkB), 140, 244, 296, 321, 490, 493, 499–500
- resiniferatoxin (RTX), 8, 9, 104, 107, 108, 115, 116, 142, 180

- Retrograde (endocannabinoid) signaling, 39, 142, 183, 188, 191, 203–208, 210–212, 214–218, 220–221, 224–227, 237–238, 250, 288, 383, 429–431, 433–436, 464, 491–492, 505, 509–510, 516, 536, 547
- Rho family of small GTPases, 248
- Rigidity, 447–448, 450
- RIM_{1α}, 205, 209
- Rimonabant. *See* *Acomplia™* and *see* *SR141716A*
- RIO (Rimonabant in Obesity), 306–307
- R-methanandamide, 92–94, 133–134, 138, 141–142, 144–145, 148, 151–153, 265, 444, 541
- RTX. *See* *resiniferatoxin*
- S**
- Sarc kinase (Src), 112–113, 139, 242
- Sativex™ (*See also: delta⁹-tetrahydrocannabinol*), 96, 379–381, 456, 490, 515
- Schizophrenia, 4, 38, 144, 153, 485–516, 533, 547
- core negative (residual) symptoms, 487, 494, 496, 498
- positive symptoms, 494
- Sensory fibres. *See* *sensory neuron*
- Sensory neuron, 8–10, 17, 25, 50, 101–102, 105, 114–117, 120, 122, 146, 174, 176–177
- SERENADE (Study Evaluating Rimonabant Efficacy in Drug-Naïve Diabetic Patients), 307–308
- serotonin, 531, 536, 542, 545, 565
- serotonin receptor, 567
- 5-HT₁, 263, 266, 487, 497, 565, 567–568
- 5-HT₂, 140, 213, 486, 488, 493, 496
- 5-HT₃, 97, 133, 135, 144, 167, 259–264, 266, 268–269
- Serotonin transporter (SERT), 134, 136, 152, 493, 535
- SERT. *See* *serotonin transporter*
- Sexual dysfunction, 375, 531, 543, 546, 568
- Signal transducer and activator of transcription (STAT), 85, 139, 242–243, 336
- Skeletal muscle, 278–279, 284–286, 289, 303
- Social (functioning and deficits), 238, 249, 485, 488, 561
- Solitary tract, 173, 242, 262, 280–281
- Spasticity, 375, 377–383, 385, 387–388, 465–466
- Spillover of glutamate, 213, 217–218, 434
- SR141716A (*See also: Acomplia™* and *rimonabant*), 7, 50, 54, 92, 95–96, 134, 136, 139, 141–142, 145–146, 148, 150, 152, 217, 262–265, 267, 287–290, 293–300, 302–303, 306–308, 320, 333–336, 345, 492, 496, 502, 544, 566
- SR144528, 52, 77, 80, 82, 92, 95, 141, 333–336, 345, 541
- Src. *See* *Sarc kinase*
- SREBP. *See* *sterol regulatory element-binding protein*
- Startle reflex. *See* *pre-pulse inhibition*
- STAT. *See* *signal transducer and activator of transcription*
- Sterol regulatory element-binding protein (SREBP), 284, 286, 297, 299, 302
- Striatum. *See* *basal ganglia*
- Substance P (*See also: neurokinin 1 (NK1) tachykinin receptor*), 121, 176, 260, 263, 426, 457
- Substance use. *See* *abuse and addiction*
- Substantia nigra, 115–116, 164, 171–172, 180, 426, 491
- pars compacta, 425, 427
- pars reticulata, 62, 425
- Subthalamic nucleus (STN), 171–172, 181, 188, 425–426, 435, 438, 451
- Suicide, 531, 534, 546, 568
- Synaptic plasticity. *See* *DSE, DSI, LTD, LTP, metaplasticity, paired-pulse facilitation and retrograde (endocannabinoid) signaling*
- T**
- Temperature sensor. *See* *TRPA₁ (formerly ANKTM₁) receptor, TRPM₈ receptor, and TRPV₁ receptor*
- Tetrahydrocannabinol. *See* *delta⁸-tetrahydrocannabinol and/or delta⁹-tetrahydrocannabinol*
- THC(s). *See* *delta⁸-tetrahydrocannabinol and/or delta⁹-tetrahydrocannabinol*
- Thermoregulation, 9, 115, 122
- TNFα. *See* *tumor necrosis factor alpha*
- Tobacco dependence/ smoking. *See* *abuse*
- Tourette's syndrome, 96, 446–447, 464, 466
- Transient release potential family vanilloid-type 1 receptor. *See* *TRPV₁ receptor*
- Traumatic brain injury, 21, 295, 343
- Tremor, 97, 375, 380, 388, 447–448, 451–452, 465–466

TrkA. *See receptor-tyrosine kinase A*
 TrkB. *See receptor-tyrosine kinase B*
 TRPA₁ (formerly ANKTM₁) receptor, 134–135, 150
 TRPC₁ receptor, 134–135, 150
 TRPM₈ receptor, 110
 TRPV₁ receptor activator/ agonist, 9, 102, 106–114, 117, 120, 133–134, 301
 antagonist, 9, 36, 50, 108, 133–134, 146, 292
 auxiliary molecule, 105–106
 cloning, 9
 desensitization, 8, 109, 116–118, 120, 150
 mRNA expression, transcriptional regulation, 109, 113–116, 291
 structure, 102–105
 splice variants, 103–105
 TRPV₄ receptor, 105, 134–135, 150
 Tumor necrosis factor alpha (TNF α), 50, 332–334, 336, 338, 340, 343–345, 348, 399–400, 455, 462
 Tumor. *See cancer*
 Type 1 cannabinoid receptor. *See CB₁ receptor*
 Type 2 cannabinoid receptor. *See CB₂ receptor*

U
 UCM707, 336, 339, 345, 417, 429, 444, 455, 460, 462
 URB597, 34, 36, 38–39, 268, 444, 541–544, 562, 567
 3'-UTR flanking region. *See CNR1*

V
 vagal, 144
 nerve, 173, 280–281
 dorsal vagal complex, 262, 270, 281
 Vanilloid. *See endovanilloid system and see TRPV₁ receptor*
 Vascular endothelial growth factor (VEGF), 365, 367–368
 VCC or VGCC (voltage-gated Ca²⁺ channel). *See Ca²⁺ channel*
 VDM11, 39, 147, 210, 222, 401, 429, 444, 460
 VEGF. *See vascular endothelial growth factor*
 Ventral tegmental area (VTA), 145, 172–173, 425, 435, 487, 491–492, 502, 508, 514, 537
 Viral infection, 347–348, 366
 Viral model, 338–339, 344, 345, 348, 376, 385
 Virodhamine, 64, 134, 136, 138, 141, 182
 Visceral fat. *See adipose tissue, white*
 Vomiting. *See nausea/ vomiting*
 VR₁. *See TRPV₁ receptor*
 VTA. *See ventral tegmental area*

W
 Weight gain, 530–531, 539, 543, 546, 549
 WIN55212–2, 77, 81, 84, 92–94, 133–134, 137–142, 144–150, 152, 227, 242, 245, 247–248, 262, 264, 292–293, 318–319, 321–322, 324, 333–336, 341, 344–345, 363, 370, 385, 398–401, 413, 435–436, 438–440, 492–493, 500, 541, 543–544, 546
 WIN55212–3, 94, 133–134, 146, 152